Sport Roche Result Belasted by the strong Swiss franc - Roche share in the minus
Scientists are trying to control lightning with a giant laser
A team of researchers from the University of Geneva has hauled a huge laser atop a mountain to shoot it at the sky and act as a high-tech lightning rod. © Univeristy of Geneva Santis, in the Swiss Alps. The team is led by Jean-Pierre Wolf, a Swiss physicist who's been working with laser for more than 20 years and has been particularly fascinated with attempting to control the weather with it. Laser creates very narrow, high-energy beams of light. Its applications range from cutting diamonds to surgery to reading barcodes, and Wolf believes he can add another to the list: protecting us from lightning.
of the Pharmaconzern Roche has benefited from a robust demand for new drugs and Covid-19 tests in the first half of the year.
The persistently high demand for Corona tests has given the Swiss pharmaconzer Roche in the first half-year tailwind. The pharmaceutical business also went back to growth for growth after a weak first quarter, which was shaped by the measures to curb the pandemic. "We've achieved good results in the first half of the year, especially thanks to the demand for our new drugs and Covid-19 tests," Treated Board Schef Severin Schwan on Thursday Balance. Roche put in the period with the tests alone 2.5 billion francs. The highlight of the demand is likely to have been achieved in the second quarter. In the second half of the year, Swan expects a decline. "Of course, if this depends on the further course of the pandemic and remain significant uncertainties."
Can Adin Hill be the No. 1 the Sharks Need?
The Sharks acquired Adin Hill over the weekend, perhaps suggesting they view the pending RFA highly for the team's future. Does the team believe in him enough to make him the No. 1 come 2021-22? © Provided by Hockey News on Sports Illustrated You don't need to be a San Jose Sharks fan to know that goaltending has been one of the team's biggest weaknesses in the past few years. Martin Jones hasn't been able to be the guy the team needed and a slew of backups haven't been able to take over the mantle.
The brand known especially for its cancer therapies from Basel is also the world's largest provider of devices, procedures and consumables to determine diseases. Last year, the mostly in the shadow of the significantly larger pharmaceutical business, diagnostic divisions moved to the limelight thanks to its corona tests. In the first half of 2021, it had a currency-adjusted sales increase of 51 percent, while sales in the pharmaceutical business fell by three percent. However, in the second quarter, there was again a sales plan of four percent to beech after a decline of nine percent in the first quarter of the year. Roche benefited from a significant growth in new drugs of 30 percent in the first half of the year, which undertaken the burdens of persistent competition by inheritance medicines. In business with cancers, the Group has not yet returned to the level in front of the pandemic.
Steelers to host former Chargers Pro Bowler Melvin Ingram on free agent visit as they seek pass rush help
Ingram spent the first nine years of his career with the ChargersPittsburgh has added few pass rushers since losing former first-round pick Bud Dupree via free agency this offseason. With training camp around the corner, they recently expressed interest in Justin Houston, the 32-year-old former Chiefs and Colts starter who remains unsigned, per La Canfora. Houston doesn't currently appear to be a fit, whether for schematic or financial reasons, so now Ingram is scheduled to visit the Steelers, along with potentially several other unsigned veterans.
A total of sales in the first half of the year climbed five percent to 30.7 billion Swiss francs, at constant exchange rates was an increase of eight percent. The company expects better than analysts. But on the stock market Roche could not score, but the Share certificates lost a good two percent.
The consolidated profit fell by three percent to 8.2 billion Swiss francs because of the strong franc, he rose by two percent in currency-adjusted. His annual targets reaffirmed Roche and unchanged at constant exchange rates with a sales increase in low to medium-sized percentage range. The earnings adjusted for special factors per title is to grow in the same amount. In the first half of the year, he increased currency-adjusted by six percent to 10.56 francs.The Roche share currently loses 1.85 percent in SIX trading to 349.35 francs.
/ NAS / MISBASEL / FRANKFURT (DPA-AFX / REUTERS)
20 Olympic countries you may have never heard of .
20 Olympic countries you may have never heard of